Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$90 Mln
P/E Ratio
--
P/B Ratio
3.13
Industry P/E
--
Debt to Equity
0.01
ROE
-0.18 %
ROCE
-17.23 %
Div. Yield
0 %
Book Value
1.09
EPS
-0.21
CFO
$-56.63 Mln
EBITDA
$-77.69 Mln
Net Profit
$-130.33 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
icad inc (ICAD)
| 87.43 | 60.28 | 0.88 | 133.33 | -2.41 | -22.40 | -10.28 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
icad inc (ICAD)
| 3.36 | -3.28 | -74.58 | -45.45 | 69.88 | 110.00 | 7.52 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.70 | 10,562.04 | 12.43 | 12.69 | |
| 73.09 | 10,050.19 | 97.07 | 2.52 | |
| 163.42 | 8,847.72 | -- | -25.23 | |
| 296.97 | 11,609.25 | 277.57 | 3.65 |
iCAD, Inc. engages in the AI-powered cancer detection solutions in the United States. The ProFound Breast Health Suite offers solutions for"breast"cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and... cardiovascular risk assessment related to elevated levels of breast arterial calcifications; as well as it also enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Detection solutions include advanced artificial intelligence and image analysis workflow solutions to identifying pathologies and pinpointing prevalent cancers earlier, a comprehensive range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. In addition, the company suite offers solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram's collection of images. Additionally, its density assessment standardizes and simplifies breast density reporting, algorithmically examining a woman's breast anatomy from the mammogram image. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire. Read more
President, CEO & Executive Chair
Ms. Dana R. Brown
President, CEO & Executive Chair
Ms. Dana R. Brown
Headquarters
Nashua, NH
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of icad inc (ICAD) stood at $ 38 Mln as on 31-Dec-24
The share price of icad inc (ICAD) is $3.43 (NASDAQ) as of 29-Apr-2025 13:40 EDT. icad inc (ICAD) has given a return of -2.41% in the last 3 years.
icad inc (ICAD) has a market capitalisation of $ 90 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of icad inc (ICAD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the icad inc (ICAD) and enter the required number of quantities and click on buy to purchase the shares of icad inc (ICAD).
iCAD, Inc. engages in the AI-powered cancer detection solutions in the United States. The ProFound Breast Health Suite offers solutions for"breast"cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; as well as it also enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Detection solutions include advanced artificial intelligence and image analysis workflow solutions to identifying pathologies and pinpointing prevalent cancers earlier, a comprehensive range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. In addition, the company suite offers solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram's collection of images. Additionally, its density assessment standardizes and simplifies breast density reporting, algorithmically examining a woman's breast anatomy from the mammogram image. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
The CEO & director of Ms. Dana R. Brown. is icad inc (ICAD), and CFO & Sr. VP is Ms. Dana R. Brown.
There is no promoter pledging in icad inc (ICAD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| icad inc (ICAD) | Ratios |
|---|---|
|
Return on equity(%)
|
-17.46
|
|
Operating margin(%)
|
-28.2
|
|
Net Margin(%)
|
-27.64
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of icad inc (ICAD) was $0 Mln.
$0.10
(
